{"title":"COVID-19 患者使用预防性 AYUSH 药物与疾病严重程度之间的关系:回顾性队列研究","authors":"Anupriya Chaudhary, Debadatta Nayak, Swati Pandey, Vipul Shastri, Madhuri Kamble, Vidya Pendse, Vismay Prajapati, Brijesh Vaidya, Heenal Rohit, Swaroopa Beedmani, Nutan Presswala, Tejaswini Patole, Ramesh Bawaskar, Vaishali Shinde, Mohua Datta, Gunjan Rai, Umakanta Prusty, Partha Pratim Pal, Siva Prasad Goli, Amulya Ratna Sahoo, K C Muraleedharan, Pooja Prakash, Ashish Mahajan, Anuradha Singh, Reetha Krishnan, Navin Pawaskar, Amit Srivastava, Gouri Devi Ningthoujam, Ravi Kumar Sadarla, Ranjit Sonny, Liyi Karso, Subhamoy Sarkar, Sunil Prasad, Ashish Kumar Shrivastava, Avinash Kumar, Nitesh Kumar, Ch Raveendar, Bsj Raja Kumar, Vspk Sastry, Asha Dasari, K Samson Sundeep, Subhash Kaushik, Padmalaya Rath, Shweta Gautam, Ratan Chandra Shil, Trupti Laxmi Swain, G Ravi Chandra Reddy, S Pradeep, S Stevenson, Gurudev Choubey, Lipipushpa Debata, Anil Khurana","doi":"10.1055/s-0044-1779693","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prior vaccination is often studied for its impact on individuals' post-infection prognosis. Ayurveda, Yoga, Unani, Siddha and Homeopathy (AYUSH) medicines, advised by the Government of India as prophylaxis during the first wave of the coronavirus disease 2019 (COVID-19) pandemic, were consumed by the masses in 2020. A study was therefore undertaken to observe any association between the prior usage of AYUSH prophylactic medicines and post-infection severity as reported by recovered COVID-19 individuals.</p><p><strong>Methods: </strong>This was a retrospective, multi-centre, cohort study conducted in 21 cities of India from 5th August to 30th November 2020. Data from recovered COVID-19 patients, of either sex or any age, captured information about AYUSH prophylactic medicines intake prior to infection, disease severity, symptomatology, duration of complaints, etc. The study participants were grouped into AYUSH intake and non-intake. Primary composite outcome was the disease clinical course. Secondary clinical outcomes were the rate of and time to clinical recovery.</p><p><strong>Results: </strong>Data of 5,023 persons were analysed. Ayurveda or homeopathic prophylactic medicines were consumed by more than half of the study participants: that is, 56.85% (<i>n</i> = 1,556) and 56.81% (<i>n</i> = 1,555) respectively. The overall adjusted protective effect (PE) of AYUSH prophylactic intake against moderate/severe forms of COVID-19 disease was 56.7% (95% confidence interval [CI], 48.7 to 63.50; <i>p</i> < 0.001). Adjusted PE for homeopathy and Siddha was 52.9% (95% CI, 42.30 to 61.50; <i>p</i> < 0.001) and 59.8% (95% CI, 37.80 to 74.10; <i>p</i> < 0.001), respectively. A statistically significant association was found between AYUSH prophylactic medicine intake and clinical recovery more frequently by the 3rd day of illness (χ<sup>2</sup> = 9.01; <i>p</i> = 0.002). Time to resolution of symptoms in the AYUSH intake group was on average 0.3 days earlier than in the non-intake group (<i>p</i> = 0.002).</p><p><strong>Conclusion: </strong>AYUSH prophylactics were associated with statistically significant levels of protection against COVID-19 disease severity. Amongst these, previous intake of homeopathy or Siddha medicines was associated with some protection against moderate/severe illness and with a somewhat quicker clinical recovery. Prospective studies with experimental research design are needed to validate the findings of this study.</p><p><strong>Study registration: </strong>Clinical Trials Registry-India (CTRI/2020/08/027000).</p>","PeriodicalId":13227,"journal":{"name":"Homeopathy","volume":" ","pages":"211-222"},"PeriodicalIF":1.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493470/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association between Usage of Prophylactic AYUSH Medicines and Disease Severity in COVID-19 Patients: A Retrospective Cohort Study.\",\"authors\":\"Anupriya Chaudhary, Debadatta Nayak, Swati Pandey, Vipul Shastri, Madhuri Kamble, Vidya Pendse, Vismay Prajapati, Brijesh Vaidya, Heenal Rohit, Swaroopa Beedmani, Nutan Presswala, Tejaswini Patole, Ramesh Bawaskar, Vaishali Shinde, Mohua Datta, Gunjan Rai, Umakanta Prusty, Partha Pratim Pal, Siva Prasad Goli, Amulya Ratna Sahoo, K C Muraleedharan, Pooja Prakash, Ashish Mahajan, Anuradha Singh, Reetha Krishnan, Navin Pawaskar, Amit Srivastava, Gouri Devi Ningthoujam, Ravi Kumar Sadarla, Ranjit Sonny, Liyi Karso, Subhamoy Sarkar, Sunil Prasad, Ashish Kumar Shrivastava, Avinash Kumar, Nitesh Kumar, Ch Raveendar, Bsj Raja Kumar, Vspk Sastry, Asha Dasari, K Samson Sundeep, Subhash Kaushik, Padmalaya Rath, Shweta Gautam, Ratan Chandra Shil, Trupti Laxmi Swain, G Ravi Chandra Reddy, S Pradeep, S Stevenson, Gurudev Choubey, Lipipushpa Debata, Anil Khurana\",\"doi\":\"10.1055/s-0044-1779693\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Prior vaccination is often studied for its impact on individuals' post-infection prognosis. Ayurveda, Yoga, Unani, Siddha and Homeopathy (AYUSH) medicines, advised by the Government of India as prophylaxis during the first wave of the coronavirus disease 2019 (COVID-19) pandemic, were consumed by the masses in 2020. A study was therefore undertaken to observe any association between the prior usage of AYUSH prophylactic medicines and post-infection severity as reported by recovered COVID-19 individuals.</p><p><strong>Methods: </strong>This was a retrospective, multi-centre, cohort study conducted in 21 cities of India from 5th August to 30th November 2020. Data from recovered COVID-19 patients, of either sex or any age, captured information about AYUSH prophylactic medicines intake prior to infection, disease severity, symptomatology, duration of complaints, etc. The study participants were grouped into AYUSH intake and non-intake. Primary composite outcome was the disease clinical course. Secondary clinical outcomes were the rate of and time to clinical recovery.</p><p><strong>Results: </strong>Data of 5,023 persons were analysed. Ayurveda or homeopathic prophylactic medicines were consumed by more than half of the study participants: that is, 56.85% (<i>n</i> = 1,556) and 56.81% (<i>n</i> = 1,555) respectively. The overall adjusted protective effect (PE) of AYUSH prophylactic intake against moderate/severe forms of COVID-19 disease was 56.7% (95% confidence interval [CI], 48.7 to 63.50; <i>p</i> < 0.001). Adjusted PE for homeopathy and Siddha was 52.9% (95% CI, 42.30 to 61.50; <i>p</i> < 0.001) and 59.8% (95% CI, 37.80 to 74.10; <i>p</i> < 0.001), respectively. A statistically significant association was found between AYUSH prophylactic medicine intake and clinical recovery more frequently by the 3rd day of illness (χ<sup>2</sup> = 9.01; <i>p</i> = 0.002). Time to resolution of symptoms in the AYUSH intake group was on average 0.3 days earlier than in the non-intake group (<i>p</i> = 0.002).</p><p><strong>Conclusion: </strong>AYUSH prophylactics were associated with statistically significant levels of protection against COVID-19 disease severity. Amongst these, previous intake of homeopathy or Siddha medicines was associated with some protection against moderate/severe illness and with a somewhat quicker clinical recovery. Prospective studies with experimental research design are needed to validate the findings of this study.</p><p><strong>Study registration: </strong>Clinical Trials Registry-India (CTRI/2020/08/027000).</p>\",\"PeriodicalId\":13227,\"journal\":{\"name\":\"Homeopathy\",\"volume\":\" \",\"pages\":\"211-222\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493470/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Homeopathy\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0044-1779693\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Homeopathy","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1055/s-0044-1779693","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
Association between Usage of Prophylactic AYUSH Medicines and Disease Severity in COVID-19 Patients: A Retrospective Cohort Study.
Background: Prior vaccination is often studied for its impact on individuals' post-infection prognosis. Ayurveda, Yoga, Unani, Siddha and Homeopathy (AYUSH) medicines, advised by the Government of India as prophylaxis during the first wave of the coronavirus disease 2019 (COVID-19) pandemic, were consumed by the masses in 2020. A study was therefore undertaken to observe any association between the prior usage of AYUSH prophylactic medicines and post-infection severity as reported by recovered COVID-19 individuals.
Methods: This was a retrospective, multi-centre, cohort study conducted in 21 cities of India from 5th August to 30th November 2020. Data from recovered COVID-19 patients, of either sex or any age, captured information about AYUSH prophylactic medicines intake prior to infection, disease severity, symptomatology, duration of complaints, etc. The study participants were grouped into AYUSH intake and non-intake. Primary composite outcome was the disease clinical course. Secondary clinical outcomes were the rate of and time to clinical recovery.
Results: Data of 5,023 persons were analysed. Ayurveda or homeopathic prophylactic medicines were consumed by more than half of the study participants: that is, 56.85% (n = 1,556) and 56.81% (n = 1,555) respectively. The overall adjusted protective effect (PE) of AYUSH prophylactic intake against moderate/severe forms of COVID-19 disease was 56.7% (95% confidence interval [CI], 48.7 to 63.50; p < 0.001). Adjusted PE for homeopathy and Siddha was 52.9% (95% CI, 42.30 to 61.50; p < 0.001) and 59.8% (95% CI, 37.80 to 74.10; p < 0.001), respectively. A statistically significant association was found between AYUSH prophylactic medicine intake and clinical recovery more frequently by the 3rd day of illness (χ2 = 9.01; p = 0.002). Time to resolution of symptoms in the AYUSH intake group was on average 0.3 days earlier than in the non-intake group (p = 0.002).
Conclusion: AYUSH prophylactics were associated with statistically significant levels of protection against COVID-19 disease severity. Amongst these, previous intake of homeopathy or Siddha medicines was associated with some protection against moderate/severe illness and with a somewhat quicker clinical recovery. Prospective studies with experimental research design are needed to validate the findings of this study.
Study registration: Clinical Trials Registry-India (CTRI/2020/08/027000).
期刊介绍:
Homeopathy is an international peer-reviewed journal aimed at improving the fundamental understanding and clinical practice of homeopathy by publishing relevant high-quality original research articles, reviews, and case reports. It also promotes commentary and debate on matters of topical interest in homeopathy.